Aliases & Classifications for Myofibroma

MalaCards integrated aliases for Myofibroma:

Name: Myofibroma 12 44 15 17 72
Solitary Myofibromatosis 72
Uterine Fibroids 72
Lipoleiomyoma 12
Myolipoma 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4386
MeSH 44 D047708
SNOMED-CT 68 44598004
UMLS 72 C0042133 C1096309 C1266121 more

Summaries for Myofibroma

MalaCards based summary : Myofibroma, also known as solitary myofibromatosis, is related to infantile myofibromatosis and hemangiopericytoma, malignant, and has symptoms including pelvic pain An important gene associated with Myofibroma is MB (Myoglobin). The drugs Leuprolide and Dienogest have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and prostate, and related phenotype is cardiovascular system.

Related Diseases for Myofibroma

Diseases related to Myofibroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 infantile myofibromatosis 32.3 PDGFRB MB DES
2 hemangiopericytoma, malignant 31.1 F13A1 DES
3 mesenchymoma 30.7 MB DES
4 liposarcoma 30.6 MB DES
5 fasciitis 30.6 ETV6 DES
6 congenital fibrosarcoma 30.5 ETV6 DES
7 myopericytoma 30.2 RELA PDGFRB
8 histiocytoma 30.2 SERPINA3 MB
9 leiomyosarcoma 29.9 PDGFRB MB DES
10 rhabdomyosarcoma 29.7 PDGFRB MB DES
11 giant cell tumor 29.7 SERPINA3 DES
12 fibrous histiocytoma 29.5 SERPINA3 F13A1 DES
13 uterine sarcoma 29.5 PDGFRB MB DES
14 uterine corpus lipoleiomyoma 12.3
15 curry-jones syndrome 11.5
16 giant cell myocarditis 10.5 MB DES
17 malignant triton tumor 10.4 MB DES
18 botryoid rhabdomyosarcoma 10.4 MB DES
19 spindle cell rhabdomyosarcoma 10.4 MB DES
20 bilateral retinoblastoma 10.4 MB DES
21 lipomatosis, multiple 10.4
22 pleomorphic lipoma 10.4
23 fibromatosis 10.4
24 exophthalmos 10.4
25 adenosarcoma 10.4 MB DES
26 leiomyoma 10.3
27 fibroblastic rheumatism 10.3 F13A1 DES
28 medullomyoblastoma 10.3 MB DES
29 angiolipoma 10.3 F13A1 DES
30 muscle cancer 10.3 MB DES
31 leiomyoma, uterine 10.3
32 cystic teratoma 10.3
33 teratoma 10.3
34 mature teratoma 10.3
35 hemangioma 10.3
36 rare tumor 10.3
37 cavernous hemangioma 10.3 MB DES
38 non-langerhans-cell histiocytosis 10.3 F13A1 DES
39 juvenile xanthogranuloma 10.3 F13A1 DES
40 embryonal rhabdomyosarcoma 10.2 MB DES
41 thymus lipoma 10.2 MB CD1A
42 immune system organ benign neoplasm 10.2 MB CD1A
43 adult fibrosarcoma 10.2 MB ETV6
44 mesenchymal cell neoplasm 10.2
45 fibrosarcoma 10.2
46 dermoid cyst 10.2
47 angiomyolipoma 10.2
48 kidney clear cell sarcoma 10.2 MB ETV6
49 alk+ histiocytosis 10.2 F13A1 CD1A
50 alveolar soft part sarcoma 10.2 MB DES

Comorbidity relations with Myofibroma via Phenotypic Disease Network (PDN):


Asherman's Syndrome Cervix Uteri Carcinoma in Situ
Chronic Salpingo-Oophoritis Endometriosis
Endometriosis of Ovary Female Stress Incontinence
Hemometra Ovarian Cancer
Salpingo-Oophoritis

Graphical network of the top 20 diseases related to Myofibroma:



Diseases related to Myofibroma

Symptoms & Phenotypes for Myofibroma

UMLS symptoms related to Myofibroma:


pelvic pain

MGI Mouse Phenotypes related to Myofibroma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.1 DES ETV6 F13A1 MB PDGFRB RELA

Drugs & Therapeutics for Myofibroma

Drugs for Myofibroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
2
Dienogest Approved Phase 4 65928-58-7
3
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
4
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
5
Desogestrel Approved Phase 4 54024-22-5 40973
6
Ethanol Approved Phase 4 64-17-5 702
7
Ferrous fumarate Approved Phase 4 141-01-5
8
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
9
leucovorin Approved Phase 4 58-05-9 143 6006
10
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
11
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
12
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
13
Zinc oxide Approved Phase 4 1314-13-2
14
Calcium carbonate Approved, Investigational Phase 4 471-34-1
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Ibuprofen Approved Phase 4 15687-27-1 3672
18
Goserelin Approved Phase 4 65807-02-5, 1233494-97-7 47725 5311128
19
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
22
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
23
Dinoprostone Approved Phase 4 363-24-6 5280360
24
Morphine Approved, Investigational Phase 4 57-27-2 5288826
25
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
26
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
27
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
28
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
29
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
30
Misoprostol Approved Phase 4 59122-46-2 5282381
31
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
32
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
35
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
38
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
39
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
40
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
41
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
42
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
43
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
46
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
47
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
48
Cobalamin Experimental Phase 4 13408-78-1 6857388
49
Fibrinolysin Investigational Phase 4 9004-09-5
50 Ulipristal acetate Phase 4 126784-99-4

Interventional clinical trials:

(show top 50) (show all 313)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
2 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
3 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
4 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
5 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
6 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
7 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
8 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
9 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
10 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
11 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
12 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
13 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
14 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
15 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
16 Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy Completed NCT03308643 Phase 4 Oxytocin
17 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
18 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
19 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
20 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
21 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
22 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
23 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
24 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
25 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
26 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
27 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
28 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
29 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
30 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
31 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
32 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
33 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
34 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
35 Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns Unknown status NCT01280045 Phase 3
36 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
37 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
38 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device Completed NCT00295217 Phase 3
39 Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT02925494 Phase 3 Estradiol/Norethindrone Acetate;Elagolix
40 Uterine Fibroids: Impact of Ulipristal Acetate 10 mg on ART Results Completed NCT02425878 Phase 3 Ulipristal Acetate;Placebo
41 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02691494 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
42 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02654054 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
43 Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone
44 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147197 Phase 3 Ulipristal acetate (UPA);Placebo
45 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147158 Phase 3 Ulipristal acetate (UPA);Placebo
46 EMMY Trial: a Randomized Comparison of Uterine Artery Embolization and Hysterectomy for the Treatment of Symptomatic Uterine Fibroids Completed NCT00100191 Phase 3
47 A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata. Completed NCT00160381 Phase 3 Asoprisnil;Asoprisnil;Placebo
48 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids Completed NCT02655224 Phase 3 Relugolix;Relugolix placebo
49 A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg
50 A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids Completed NCT02655237 Phase 3 Relugolix;Relugolix Placebo;Leuprorelin;Leuprorelin Placebo

Search NIH Clinical Center for Myofibroma

Cochrane evidence based reviews: myofibroma

Genetic Tests for Myofibroma

Anatomical Context for Myofibroma

MalaCards organs/tissues related to Myofibroma:

41
Uterus, Breast, Prostate, Bone, Testes, Liver, Smooth Muscle

Publications for Myofibroma

Articles related to Myofibroma:

(show top 50) (show all 2879)
# Title Authors PMID Year
1
Ginsenoside Rb1 inhibits proliferation and promotes apoptosis by regulating HMGB1 in uterine fibroid cells. 38
31313594 2019
2
Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC). 38
31162287 2019
3
Expression of annexin A2 in adenomyosis and dysmenorrhea. 38
31183557 2019
4
Rapidly progressing myofibroma of the gingiva - a rare occurrence. 38
31208789 2019
5
Myopericytoma at the Craniocervical Junction: Clinicopathological Report and Review of a Rare Perivascular Neoplasm. 38
29889275 2019
6
Analysis of risk factors and predictors of pregnancy loss and strategies for the management of cervical insufficiency in pregnant women at a high risk of preterm birth. 38
31409178 2019
7
Uterine-sparing management of pyomyoma after uterine fibroid embolization. 38
31236185 2019
8
Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study. 38
31392917 2019
9
Efficacy and safety of ultrasound-guided high-intensity focused ultrasound for uterine fibroids: a preliminary experience. 38
31006301 2019
10
Analysis of medication data of women with uterine fibroids based on data mining technology. 38
31422040 2019
11
A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids. 38
31127621 2019
12
Term Delivery in an Infertile Patient after Transcervical Radiofrequency Fibroid Ablation and Assisted Reproductive Technology. 38
31406455 2019
13
Effects of selective serotonin reuptake inhibitors on motility of isolated fallopian tube. 38
31168867 2019
14
Wearable haptic interfaces for applications in gynecologic robotic surgery: a proof of concept in robotic myomectomy. 38
31062181 2019
15
Benign tumors in myotonic dystrophy type I target disease-related cancer sites. 38
31402615 2019
16
Placental complications in subsequent pregnancies after prior cesarean section performed in the first versus second stage of labor. 38
31416380 2019
17
Total laparoscopic hysterectomy for enlarged uteri: factors associated with the rate of conversion to open surgery. 38
31001998 2019
18
A tissue preparation to characterize uterine fibroid tissue properties for thermal therapies. 38
31152601 2019
19
Intraoperative ultrasound-assisted enucleation of residual fibroids following laparoscopic myomectomy. 38
29763581 2019
20
The impact of uterine artery embolization on ovarian reserve: a systematic review and meta-analysis. 38
31370100 2019
21
The Effectiveness of Tranexamic Acid at Reducing Blood Loss and Transfusion Requirement for Women Undergoing Myomectomy: A Systematic Review and Meta-analysis. 38
30385210 2019
22
A case-control study of the relationship between visceral fat and development of uterine fibroids. 38
31258679 2019
23
Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. 38
31288815 2019
24
The association between childbirth, breastfeeding, and uterine fibroids: an observational study. 38
31300699 2019
25
Comprehensive feature selection for classifying the treatment outcome of high-intensity ultrasound therapy in uterine fibroids. 38
31358836 2019
26
Successful endovascular recanalization of massive cerebral venous sinus thrombosis in a patient with tuberous sclerosis and protein S deficiency: a case report. 38
31312460 2019
27
Spontaneous coronary artery dissection in a woman undergoing pseudomenopause therapy with leuprorelin: A case report. 38
31320945 2019
28
Ultrasound assessment of uterine morphology in menorrhagia: case control study. 38
31352859 2019
29
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. 38
30853364 2019
30
Uterine Artery Embolization (UAE) for Fibroid Treatment - Results of the 7th Radiological Gynecological Expert Meeting. 38
31137043 2019
31
MR-Guided Focused Ultrasound in Fibroid Treatment - Results of the 4th Radiological-Gynecological Expert Meeting. 38
31137044 2019
32
Minimally Invasive Myomectomy: An Overview on the Surgical Approaches and a Comparison with Mini-Laparotomy. 38
31322011 2019
33
Uterine Artery Embolization (UAE) for Fibroid Treatment - Results of the 7th Radiological Gynecological Expert Meeting. 38
31354165 2019
34
MR-Guided Focused Ultrasound in Fibroid Treatment - Results of the 4th Radiological-Gynecological Expert Meeting. 38
31354166 2019
35
Anaplastic ependymoma arising from the lower segment of the uterine corpus: Case report and literature review. 38
31060102 2019
36
Uterine fibroid management: Today and tomorrow. 38
31141843 2019
37
Intraoperative transradial angiography augments safe hysterectomy for uterine fibroids in the setting of ambiguous arterial anatomy: a case report. 38
31352903 2019
38
Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment. 38
30478352 2019
39
Healthcare resource utilization and costs among women diagnosed with uterine fibroids (UF) compared to women without UF. 38
31290716 2019
40
The mitochondrial DNA 4977-bp deletion and copy number alteration in Han Chinese samples with uterine fibroids. 38
30821350 2019
41
Application of UPLC-MS/MS to simultaneously detect four bioactive compounds in the tumour-shrinking decoction (FM1523) for uterine fibroids treatment. 38
30916852 2019
42
H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. 38
31089260 2019
43
Delphi Approach for the Design of an Intraoperative Blood Conservation Pathway for Open Myomectomy. 38
31296447 2019
44
Solitary orbital myofibroma in a child: A rare case report with literature review. 38
31238482 2019
45
Evaluation of the routine use of pelvic MRI in women presenting with symptomatic uterine fibroids: When is pelvic MRI useful? 38
30614145 2019
46
Aberrant Hypermetabolism of Benign Uterine Leiomyoma on 18F-FDG PET/CT. 38
30985441 2019
47
Current facts constituting an understanding of the nature of adenomyosis. 38
30085434 2019
48
Ultrasound-Guided High Intensity Focused Ultrasound Ablation for Symptomatic Uterine Fibroids: Preliminary Clinical Experience. 38
31238385 2019
49
1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids. 38
30514160 2019
50
Predictive Value of Quantitative Uterine Fibroid Perfusion Parameters From Contrast-Enhanced Ultrasound for the Therapeutic Effect of High-Intensity Focused Ultrasound Ablation. 38
30286521 2019

Variations for Myofibroma

Expression for Myofibroma

Search GEO for disease gene expression data for Myofibroma.

Pathways for Myofibroma

GO Terms for Myofibroma

Cellular components related to Myofibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 SERPINA3 F13A1

Biological processes related to Myofibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hydrogen peroxide GO:0042542 8.8 RELA PDGFRB MB

Sources for Myofibroma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....